1-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-4-(2-chloropyridine-3-carbonyl)piperazine

Catalog No. :
ACJQPD371
CAS No. :
303149-94-2
Molecular Formula :
C16H13Cl2F3N4O
Molecular Weight :
405.21

IUPAC Name:(4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)(2-chloropyridin-3-yl)methanone

1-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-4-(2-chloropyridine-3-carbonyl)piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$293.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-4-(2-chloropyridine-3-carbonyl)piperazine
IUPAC Name(4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)(2-chloropyridin-3-yl)methanone
Molecular FormulaC16H13Cl2F3N4O
Molecular Weight405.21
SMILESO=C(N1CCN(C2=NC=C(C(F)(F)F)C=C2Cl)CC1)C3=CC=CN=C3Cl
InChI KeyTXIZIQXAGFENSP-UHFFFAOYSA-N
Synonym(2-CHLORO-3-PYRIDINYL)(4-[3-CHLORO-5-(TRIFLUOROMETHYL)-2-PYRIDINYL]PIPERAZINO)METHANONE;1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-4-(2-chloropyridine-3-carbonyl)piperazine;Methanone, (2-chloro-3-pyridinyl)[4-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-
CAS No.303149-94-2

Synthetic Route by SureRoute

1. ACJQPD371 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSFLO426 route compound structure diagram
    ACSFLO426132834-59-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJQPD371 route product structure diagram
    ACJQPD371303149-94-2
Inquiry

2. ACJQPD371 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSFLO426 route compound structure diagram
    ACSFLO426132834-59-4 In Stock
  2. Plus
  3. ACCOGW615 route compound structure diagram
    ACCOGW61549609-84-9 In Stock
  4. Then
  5. ACJQPD371 route product structure diagram
    ACJQPD371303149-94-2
Inquiry

Comments (0)